Holen Sie sich die Stockscreener-App
14.34
3.68%
0.49
Schlusskurs vom Vortag:
$13.85
Offen:
$14.01
24-Stunden-Volumen:
68,826
Relative Volume:
0.11
Marktkapitalisierung:
$745.25M
Einnahmen:
$217.25M
Nettoeinkommen (Verlust:
$-50.92M
KGV:
-10.10
EPS:
-1.42
Netto-Cashflow:
$-100.85M
1W Leistung:
-8.77%
1M Leistung:
-4.27%
6M Leistung:
-29.57%
1J Leistung:
-62.74%
1-Tages-Spanne:
$13.78
$14.50
1-Wochen-Bereich:
$12.79
$15.80
52-Wochen-Spanne:
$11.70
$41.55
Prothena Corporation Plc Stock (PRTA) Company Profile
Firmenname
Prothena Corporation Plc
Sektor
Branche
Telefon
011-353-1-236-2500
Adresse
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Vergleichen Sie PRTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
14.33 | 745.25M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.66 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.10 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
625.21 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.41 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.44 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-01-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-04-24 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-27 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-06-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Oppenheimer | Outperform |
| 2021-05-26 | Eingeleitet | Citigroup | Buy |
| 2021-02-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-05-21 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-04-23 | Herabstufung | Jefferies | Buy → Hold |
| 2018-04-05 | Bestätigt | Barclays | Overweight |
| 2017-11-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2017-09-29 | Bestätigt | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Jefferies | Buy |
| 2017-04-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-12-21 | Eingeleitet | SunTrust | Buy |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-08-04 | Bestätigt | Barclays | Overweight |
| 2016-05-13 | Eingeleitet | Barclays | Overweight |
| 2016-02-19 | Bestätigt | Wedbush | Outperform |
| 2016-01-21 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Prothena Corporation Plc Aktie (PRTA) Neueste Nachrichten
Prothena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Prothena (NASDAQ:PRTA) Stock Price Down 2.6%Should You Sell? - MarketBeat
Prothena Corporation PLC (NASDAQ:PRTA) Director Oleg Nodelman Resigns - Defense World
Prothena Director Oleg Nodelman Steps Down After 5-Year Tenure, Ahead of Major 2025 Clinical Milestones - StockTitan
Prothena Co. plc (NASDAQ:PRTA) Shares Sold by Geode Capital Management LLC - Defense World
Prothena Co. plc (NASDAQ:PRTA) Shares Bought by Barclays PLC - Defense World
Barclays PLC Buys 49,916 Shares of Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
How the (PRTA) price action is used to our Advantage - Stock Traders Daily
Prothena Co. plc (NASDAQ:PRTA) Position Trimmed by State Street Corp - Defense World
Prothena Co. plc (NASDAQ:PRTA) Holdings Decreased by State Street Corp - MarketBeat
Prothena Surges After Parkinson's Drug Misses Primary Endpoint - Seeking Alpha
Prothena (NASDAQ:PRTA) Earns Buy Rating from HC Wainwright - MarketBeat
Prothena (NASDAQ:PRTA) Coverage Initiated at Chardan Capital - MarketBeat
Demystifying Prothena Corp: Insights From 6 Analyst Reviews - Benzinga
Even after rising 16% this past week, Prothena (NASDAQ:PRTA) shareholders are still down 67% over the past three years - Simply Wall St
Prothena Corp (NASDAQ:PRTA) Stock Quotes, Forecast and News Summary - Benzinga
Prothena Shares Surge 43% Despite Setback in Parkinson's Drug Trial, Investors Eye Future Potential - mediahousepress
Prothena stock soars despite study miss By Investing.com - Investing.com Canada
Prothena stock soars despite study miss - Investing.com
Prothena (NASDAQ:PRTA) Price Target Cut to $22.00 by Analysts at Bank of America - MarketBeat
Why Is Prothena Corp Stock Soaring Today?Roche Holding (OTC:RHHBY) - Benzinga
Prothena shares price target cut after Parkinson's study miss By Investing.com - Investing.com UK
Prothena stock gains despite Parkinson’s setback (RHHBY:OTCQX) - Seeking Alpha
Prothena’s Parkinson’s study fails primary endpoint despite some success - Yahoo Finance
Prothena (NASDAQ:PRTA) Hits New 52-Week LowHere's Why - MarketBeat
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease - Business Wire
Prothena (NASDAQ:PRTA) Stock Price Down 3.6%Should You Sell? - MarketBeat
Prothena (NASDAQ:PRTA) Stock Price Up 7.8%What's Next? - MarketBeat
Where are the Opportunities in (PRTA) - Stock Traders Daily
Prothena's SWOT analysis: biotech stock's high-risk, high-reward pipeline - Investing.com
Oppenheimer bullish on Prothena stock, sees $1B opportunity for birtamimab in rare disease - Investing.com Nigeria
Janus Henderson Group PLC Sells 1,008,511 Shares of Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena (NASDAQ:PRTA) Reaches New 1-Year LowWhat's Next? - MarketBeat
Charles Schwab Investment Management Inc. Decreases Stock Position in Prothena Co. plc (NASDAQ:PRTA) - Defense World
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report? - Yahoo Finance
Wellington Management Group LLP Has $69.91 Million Holdings in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
FY2024 EPS Estimates for Prothena Increased by Analyst - MarketBeat
Systematic Financial Management LP Sells 185,638 Shares of Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
FY2024 EPS Estimates for Prothena Raised by Zacks Research - Defense World
Prothena's SWOT analysis: high-risk pipeline stock faces crucial readouts - Investing.com India
Prothena's SWOT analysis: high-risk pipeline stock faces crucial readouts By Investing.com - Investing.com South Africa
Learn to Evaluate (PRTA) using the Charts - Stock Traders Daily
Prothena (NASDAQ:PRTA) Rating Lowered to “Sell” at StockNews.com - Defense World
Prothena FY2024 EPS Forecast Raised by Cantor Fitzgerald - Defense World
Prothena FY2024 EPS Forecast Boosted by Cantor Fitzgerald - MarketBeat
FY2024 EPS Estimates for Prothena Reduced by HC Wainwright - MarketBeat
Prothena (NASDAQ:PRTA) Hits New 12-Month LowHere's What Happened - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Receives $61.86 Average PT from Brokerages - Defense World
FY2028 EPS Estimates for Prothena Increased by HC Wainwright - MarketBeat
Finanzdaten der Prothena Corporation Plc-Aktie (PRTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Prothena Corporation Plc-Aktie (PRTA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Walker Karin L | Chief Accounting Officer |
Jan 24 '24 |
Sale |
34.00 |
5,000 |
170,000 |
0 |
1.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):